Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nautilus Biotechnology, Inc. (NAUT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed development stage life sciences company building a single-molecule proteome analysis platform, Nautilus uses filings such as Forms 10-K, 10-Q, and 8-K to report financial results, operational updates, and other material events related to its business.
Investors reviewing NAUT filings can examine periodic reports for details on research and development and general and administrative expenses, net losses, and cash, cash equivalents, and investments, which reflect the company’s development stage profile. These filings also describe risk factors associated with Nautilus’ efforts to develop and validate its proteome analysis platform, including the scientific and technical challenges of bringing a highly novel product to market and uncertainties around timelines for validation and commercialization.
Current reports on Form 8-K are particularly relevant for tracking significant events at Nautilus. For example, the company has filed 8-Ks to furnish quarterly earnings press releases and to disclose matters such as the outcome of its annual meeting of stockholders and changes in Nasdaq listing status. One Form 8-K describes a notice from Nasdaq indicating that Nautilus had not met the minimum bid price requirement for continued listing on the Nasdaq Global Select Market and the subsequent transfer to The Nasdaq Capital Market. A later Form 8-K reports that Nautilus regained compliance with Nasdaq’s minimum bid price rule after its closing bid price met or exceeded $1.00 per share for at least ten consecutive business days.
Through this page, users can also monitor governance-related disclosures, including information about director elections and auditor ratification reported under Item 5.07 of Form 8-K. In addition, Nautilus’ filings reference its status as an emerging growth company and its use of SEC filings, press releases, webcasts, and its website as channels for disclosing material information. Stock Titan’s interface surfaces these filings with AI-powered summaries that help explain the context and key points, allowing readers to quickly understand the implications of lengthy documents such as annual reports, quarterly reports, and current reports on Form 8-K without reading every line.
The filing is a Form 4 dated 06/24/2025 reporting insider activity at Nautilus Biotechnology, Inc. (ticker NAUT). Director Matthew L. Posard was granted a stock option covering 45,000 common shares at an exercise price of $0.6951 per share. The option was issued on 06/23/2025, vests in twelve equal monthly installments as long as Mr. Posard remains a “Service Provider,” and expires on 06/23/2035. After the transaction, Mr. Posard beneficially owns 45,000 derivative securities, all held directly. No common shares were bought or sold on the open market; the filing reflects an incentive-based equity award only.
Form 4 snapshot: On 06/23/2025, Nautilus Biotechnology, Inc. (ticker NAUT) filed a Form 4 disclosing that director Matthew S. McIlwain received a new equity award.
- Instrument granted: Non-qualified stock option (right to buy common shares).
- Quantity: 45,000 option units.
- Exercise price: $0.6951 per share.
- Expiration: 06/23/2035 (10-year term).
- Vesting schedule: Subject to the director’s continued “Service Provider” status, one-twelfth (1/12) of the option vests monthly after the grant date, fully vesting over one year.
- Post-transaction holdings: McIlwain now beneficially owns 45,000 derivative securities (options) directly; no non-derivative share activity was reported.
- Transaction code: “A” (grant) – no open-market purchase or sale; zero cash proceeds reported.
The filing indicates routine board compensation designed to align the director’s incentives with shareholder returns. No shares were sold or purchased, and there is no indication of additional indirect ownership or Rule 10b5-1 trading plan usage. Overall, the disclosure is limited to a single option grant and does not introduce immediate dilution or cash flow impact for the company.
Form 4 snapshot – Nautilus Biotechnology, Inc. (NAUT)
On 06/23/2025 director Farzad Nazem received a grant of 45,000 non-qualified stock options with an exercise price of $0.6951 per share. The options expire on 06/23/2035 and vest monthly in 12 equal instalments, contingent on Mr. Nazem’s continued service to the company. Following the grant, the director’s beneficial ownership in derivative securities increased by 45,000 options; no open-market purchase or sale of common stock occurred.
- The filing is an initial disclosure of an equity award rather than a transaction involving NAUT shares on the secondary market.
- The awarded option strike price is close to the company’s recent trading range, suggesting alignment of director incentives with future share appreciation.
- The total grant represents an immaterial <0.1% potential dilution based on NAUT’s ~124 million shares outstanding.
No other securities were acquired or disposed of, and no Rule 10b5-1 trading plan was indicated.
Form 4 overview: Nautilus Biotechnology, Inc. (NAUT) reported that director Karen Akinsanya received a new equity award on 06/23/2025.
- Instrument: Stock Option (right to buy common stock)
- Quantity granted: 45,000 options
- Exercise price: $0.6951 per share
- Expiration: 06/23/2035 (10-year term)
- Vesting schedule: 1/12 of the award vests monthly, provided Akinsanya maintains “Service Provider” status under the company’s 2021 Equity Incentive Plan.
- Ownership after grant: 45,000 derivative securities; no direct common-stock position was disclosed in this filing.
- Transaction code: “A” (acquisition), indicating an award rather than an open-market purchase or sale.
- Signatory: Mathew B. Murphy (Attorney-in-Fact) on 06/24/2025.
Investor takeaways: The filing records a routine director compensation grant. It does not involve a cash transaction, does not change outstanding share count immediately, and entails limited short-term financial impact. The options could become dilutive if exercised, but that would occur only once the exercise price is met and the director elects to convert.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed Amendment No. 4 to Schedule 13D for Nautilus Biotechnology, Inc. (NAUT) on 24 June 2025. The filing discloses that the reporting group continues to hold 12,815,113 common shares, equal to 10.1 % of NAUT’s 126,148,469 shares outstanding as reported in the company’s 29 April 2025 proxy statement. The position is held on a shared voting and dispositive basis; none of the reporting persons has sole power over the shares.
The stake includes 220,902 shares underlying stock options granted to Michael Altman, a Perceptive Managing Director whose related director compensation is offset against Master Fund fees. Importantly, Mr. Altman ceased serving on Nautilus’s board effective 20 June 2025 when his term expired and he did not stand for re-election. No changes to share ownership levels were reported in this amendment—its primary purpose is to reflect the board-service change and update ownership calculations to the latest outstanding-share figure.
Key takeaways for investors:
- The Perceptive group remains a double-digit owner, preserving potential influence through its economic stake even after losing direct board representation.
- The departure of Perceptive’s board designee may reduce the group’s informational access and governance leverage.
- No purchase or sale of NAUT shares is disclosed; percentages changed only because the outstanding-share count was updated.